QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
Log in
NYSE:MRK

Merck & Co., Inc. Stock Forecast, Price & News

$80.39
+0.53 (+0.66 %)
(As of 11/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$79.41
Now: $80.39
$80.54
50-Day Range
$75.21
MA: $79.48
$81.50
52-Week Range
$65.25
Now: $80.39
$92.64
Volume13.35 million shs
Average Volume10.41 million shs
Market Capitalization$203.39 billion
P/E Ratio17.79
Dividend Yield3.06%
Beta0.42
Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic and preventive agents for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. It provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, esophageal, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. In addition, the company offers drugs for hepatocellular and merkel cell carcinoma; antibiotic and anti-inflammatory drugs for infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticides for sea lice in salmon; and antibiotics and vaccines for fish. Further, it provides companion animal products; diabetes mellitus treatment and anthelmintic products for dogs and cats; products to treat fleas, ticks, mosquitoes, and sandflies; horse fertility management products for swine; and dog, cat, and horse vaccines. Additionally, the company offers services and solutions that focus on engagement, clinical, and health analytics. Merck & Co., Inc. has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Almac Discovery Ltd.; Skyhawk Therapeutics, Inc.; Ridgeback Biotherapeutics; Shanghai Junshi Biosciences Co., Ltd.; FUJIFILM Corporation; Intec Pharma Ltd.; and Transcenta Holding Ltd. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers; and physicians and physician distributors, veterinarians, and animal producers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Merck & Co., Inc. logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.40 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP58933Y10
Phone908-740-4000
Employees71,000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$46.84 billion
Cash Flow$6.67 per share
Book Value$10.21 per share

Profitability

Net Income$9.84 billion

Miscellaneous

Outstanding Shares2,530,034,000
Market Cap$203.39 billion
Next Earnings Date2/3/2021 (Estimated)
OptionableOptionable
$80.39
+0.53 (+0.66 %)
(As of 11/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

How has Merck & Co., Inc.'s stock price been impacted by Coronavirus (COVID-19)?

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MRK stock has increased by 1.4% and is now trading at $80.39.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Merck & Co., Inc.?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Merck & Co., Inc.
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Merck & Co., Inc.?

Wall Street analysts have given Merck & Co., Inc. a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Merck & Co., Inc. wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Merck & Co., Inc.
.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) announced its quarterly earnings results on Tuesday, October, 27th. The company reported $1.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.44 by $0.30. The business earned $12.55 billion during the quarter, compared to the consensus estimate of $12.21 billion. Merck & Co., Inc. had a return on equity of 55.13% and a net margin of 24.33%. The business's revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.51 EPS.
View Merck & Co., Inc.'s earnings history
.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. declared a quarterly dividend on Tuesday, November 17th. Investors of record on Tuesday, December 15th will be given a dividend of $0.65 per share on Friday, January 8th. This represents a $2.60 annualized dividend and a yield of 3.23%. The ex-dividend date is Monday, December 14th. This is an increase from Merck & Co., Inc.'s previous quarterly dividend of $0.61.
View Merck & Co., Inc.'s dividend history
.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. updated its FY20 earnings guidance on Tuesday, October, 27th. The company provided earnings per share (EPS) guidance of $5.91-6.01 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.54. The company issued revenue guidance of $47.6-48.6 billion, compared to the consensus revenue estimate of $48.01 billion.

What price target have analysts set for MRK?

15 brokers have issued twelve-month price objectives for Merck & Co., Inc.'s stock. Their forecasts range from $88.00 to $105.00. On average, they expect Merck & Co., Inc.'s stock price to reach $95.33 in the next year. This suggests a possible upside of 18.6% from the stock's current price.
View analysts' price targets for Merck & Co., Inc.
.

Are investors shorting Merck & Co., Inc.?

Merck & Co., Inc. saw a increase in short interest during the month of October. As of October 30th, there was short interest totaling 14,750,000 shares, an increase of 40.1% from the October 15th total of 10,530,000 shares. Based on an average daily volume of 8,230,000 shares, the days-to-cover ratio is currently 1.8 days. Approximately 0.6% of the company's stock are short sold.
View Merck & Co., Inc.'s Short Interest
.

Who are some of Merck & Co., Inc.'s key competitors?

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), The Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and The Home Depot (HD).

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the following people:
  • Mr. Kenneth C. Frazier, Chairman, Pres & CEO (Age 65, Pay $6.64M)
  • Mr. Robert M. Davis, Exec. VP of Global Services & CFO (Age 53, Pay $3.29M)
  • Ms. Jennifer L. Zachary, Exec. VP, Gen. Counsel & Corp. Sec. (Age 42, Pay $2.47M)
  • Mr. Sanat Chattopadhyay, Exec. VP & Pres of Merck Manufacturing Division (Age 60, Pay $2.01M)
  • Dr. Roger M. Perlmutter, Exec. VP & Pres of Merck Research Laboratories (Age 68, Pay $3.55M)
  • Mr. David Michael Williams, Chief Information & Digital Officer
  • Mr. Peter Dannenbaum CFA, VP of Investor Relations
  • Michael W. Fleming, Sr. VP and Chief Ethics & Compliance Officer (Age 61)
  • Jennifer Mauer, VP of Global Communications
  • Mr. Michael T. Nally, Chief Marketing Officer & Exec. VP (Age 44)

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (4.63%), Massachusetts Financial Services Co. MA (0.95%), Nuveen Asset Management LLC (0.80%), Morgan Stanley (0.76%), UBS Asset Management Americas Inc. (0.49%) and Charles Schwab Investment Management Inc. (0.46%). Company insiders that own Merck & Co., Inc. stock include Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Richard R Deluca, Rita A Karachun, Robert M Davis, Sanat Chattopadhyay, Thomas H Glocer and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc.
.

Which major investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Ninety One UK Ltd, Point72 Asset Management L.P., State Street Corp, The Manufacturers Life Insurance Company, State of Tennessee Treasury Department, Achmea Investment Management B.V., and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Frank Clyburn, Julie L Gerberding, Robert M Davis, Sanat Chattopadhyay, and Wendell P Weeks.
View insider buying and selling activity for Merck & Co., Inc.
.

Which major investors are buying Merck & Co., Inc. stock?

MRK stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Samlyn Capital LLC, DekaBank Deutsche Girozentrale, Candriam Luxembourg S.C.A., Natixis, Morgan Stanley, Alecta Pensionsforsakring Omsesidigt, and Douglass Winthrop Advisors LLC.
View insider buying and selling activity for Merck & Co., Inc.
.

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $80.39.

How big of a company is Merck & Co., Inc.?

Merck & Co., Inc. has a market capitalization of $203.39 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe.

What is Merck & Co., Inc.'s official website?

The official website for Merck & Co., Inc. is www.merck.com.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]

This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.